

Clinical Trial Results

Clinical Trial Protocol Number	EMR200559006
Title	A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon- β -1a 30 μ g IM Weekly in Subjects with Relapsing-Remitting Multiple Sclerosis
Trial Phase	III
EudraCT Number	2013-002351-15
Sponsor*	Merck KGaA Frankfurter Strasse 250, 64293, Darmstadt, Germany
Primary Objectives	The primary objective of this trial is to demonstrate the effect of ONO 4641 versus interferon (IFN) β 1a (Avonex) 30 μ g on the proportion of subjects, with relapsing-remitting multiple sclerosis (RRMS), who remain qualifying relapse-free during their participation in the trial when the last evaluable subject completes 1 year.
Overall Trial Status	Prematurely Ended (no patients have been enrolled)
Reason for Trial Cancellation	Discontinuation of development program.

*On June 17, 2014 Merck announced that it has reached a mutual agreement with Ono Pharmaceutical Co., Ltd., Osaka, Japan, to terminate the license agreement on ceralifimod (ONO-4641)

<https://www.merckgroup.com/press-releases/2014/jun/en/Ono-Pharmaceutical-Ceralifimod-EN.pdf>

Merck KGaA

These results are supplied for information purposes only.